# Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.

> **NCT04614493** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 66 (estimated)

## Conditions studied

- Initial Radiological Diagnosis Eligible for Tumor Resection
- Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type)
- Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide

## Interventions

- **DEVICE:** SonoCloud-9 (SC9) device
- **DRUG:** Temozolomide according Stupp protocol

## Key facts

- **NCT ID:** NCT04614493
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-11
- **Primary completion:** 2024-03
- **Final completion:** 2024-03
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04614493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04614493, "Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04614493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*